Agenus (AGEN) Long-Term Investments (2025 - 2026)

Agenus' (AGEN) quarterly Long-Term Investments came in at $22.9 million in Q1 2026, down 5.56% quarter-over-quarter from $24.3 million in Q4 2025.

Agenus (AGEN) Long-Term Investments (2025 - 2026) Analysis & Trends

Agenus' Long-Term Investments history runs 2 years deep, the most recent figure standing at $22.9 million for Q1 2026.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $22.9 million in Q1 2026; TTM through Mar 2026 was $22.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $24.3 million, changed N/A from the prior year.
Long-Term Investments retreated to $22.9 million in Q1 2026 per AGEN's latest filing, from $24.3 million in the prior quarter.
Across five years, Long-Term Investments topped out at $30.5 million in Q3 2025 and bottomed at $22.9 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Agenus	184.05 Mn	177.29 Mn	33.74 Mn	22.93 Mn

Download Data